Vmbook Online ordering
Multicell Technologies Inc
MEI Pharma, Inc. is a biotechnology business that is publicly traded in the United States under the ticker symbol MCEL. On September 2, 2022, the business changed its name from MEI Pharma, Inc. to Mersana Therapeutics, Inc., but the ticker symbol remained the same.
MEI Pharma focuses on the development and commercialization of novel drugs for treating cancer. MEI Pharma was founded in 2000, and its main office is in San Diego, California.
The business's product candidates include ublituximab, which is being developed to treat a range of cancers, including B-cell malignancies and multiple sclerosis. MEI Pharma is also creating various immuno-oncology treatments aimed at enhancing clinical outcomes for patients with cancer.
According to Yahoo Finance, as of September 12, MEI Pharma's stock price has fallen 36.76% over the past year, while its one-year revenue growth is -4.32%. The business has a $479.65 million market capitalization and a price-to-earnings ratio of 26.63. The stock's 52-week high and low are $8.00 and $4.23, respectively.
MEI Pharma has a beta of 2.01, which indicates that its stock price movement has been more volatile than the market. The company has no debt and $134.47 million in cash, as stated in its most recent quarterly report. MEI Pharma has a higher return on equity than 93.94% of US-listed companies in the biotechnology industry, with a negative return on equity of 47.5%.
The business is expanding its workforce and has 37 job openings as of September 12.
MEI Pharma's development pipeline includes ublituximab, which is in phase 3 clinical trials for the treatment of multiple sclerosis and B-cell malignancies, and several immunotherapy treatments in various stages of clinical development.
The business is a clinical-stage biotechnology corporation that focuses on the creation of novel drugs for cancer treatment.
MEI Pharma's stock has declined over the previous year, while its one-year revenue growth is negative. The corporation has a sizable amount of cash on hand and no debt. The business is expanding its workforce and pipeline of products, concentrating on the creation of innovative cancer treatments.